

325. Arranz R, Yañez E, Franceschi JL, et al. More about omeprazole-cyclosporine interaction [correspondence]. *Am J Gastroenterol* 1993; 88: 154
326. Schouler L, Dumas F, Couzigou P, et al. Omeprazole-cyclosporin interaction [correspondence]. *Am J Gastroenterol* 1991; 86: 1097
327. Gerber MC, Tejwani GA, Gerber N, et al. Drug interactions with cimetidine: an update. *Pharmacol Ther* 1985; 27: 353-70
328. Hansten PD. Drug interactions with antiseecretory agents. *Aliment Pharmacol Ther* 1991; 5 Suppl. 1: 121-8
329. Armstrong D, Nicolet M, Monnier P, et al. Maintenance therapy: is there still a place for antireflux surgery? *World J Surg* 1992; 16: 300-7
330. Partipilo ML, Woster PS. The role of *Helicobacter pylori* in peptic ulcer disease. *Pharmacotherapy* 1993; 13: 330-9
331. Barradell LB, Whittington R, Benfield P. Misoprostol. Pharmacoeconomics of its use as prophylaxis against gastroduodenal damage induced by nonsteroidal anti-inflammatory drugs. *Pharmacoeconomics* 1993; 3: 140-70
332. Bolten W, Miehke K. Therapie und Prävention der nichtsteroidalen Antirheumatika-assoziierten Gastropathie. *Med Welt* 1992; 43: 831-9
333. Fenn GC. Protection of the gastric mucosa from NSAIDs. [correspondence]. *NZ Med J* 1992; 105: 436
334. Fenn GC, Robinson GC. Misoprostol – a logical therapeutic approach to gastroduodenal mucosal injury induced by nonsteroidal anti-inflammatory drugs? *J Clin Pharm Ther* 1991; 16: 385-409
335. Kühler T, Fryklund J, Bergman N-Å, et al. Omeprazole and analogues inhibit urea-dependent ammonia production by *Helicobacter pylori*. Astra Hässle, Sweden, data on file
336. Schönhöfer PS. Safety of omeprazole and lansoprazole [correspondence]. *Lancet* 1994; 343: 1369-70

---

Correspondence: *Michelle I. Wilde*, Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand.

---

#### Erratum

**Vol. 47, No. 4, 1994, page 695:** The second sentence in the second paragraph in the right-hand column should read, 'Administration of ferrous sulphate . . . reduced the relative bioavailability of levofloxacin 100mg to 81, 78 and 56% in healthy volunteers compared with controls, . . .'.

[*Davis R, Bryson HM. Levofloxacin: a review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 1994; 47: 677-700*]